Galmed Pharmaceuticals (GLMD) Stock Price Down 10.6%

Share on StockTwits

Galmed Pharmaceuticals Ltd (NASDAQ:GLMD)’s share price was down 10.6% during trading on Thursday . The stock traded as low as $15.90 and last traded at $16.06. Approximately 1,374,895 shares changed hands during mid-day trading, an increase of 429% from the average daily volume of 259,953 shares. The stock had previously closed at $17.96.

Several equities analysts have commented on GLMD shares. ValuEngine cut shares of Galmed Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, February 14th. Zacks Investment Research raised shares of Galmed Pharmaceuticals from a “hold” rating to a “buy” rating and set a $6.50 price target for the company in a research report on Tuesday, May 15th. Maxim Group set a $14.00 price target on shares of Galmed Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, May 9th. Finally, HC Wainwright raised their price target on shares of Galmed Pharmaceuticals from $24.00 to $43.00 and gave the company a “buy” rating in a research report on Tuesday. Five analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Galmed Pharmaceuticals has an average rating of “Buy” and an average target price of $26.92.

The stock has a market cap of $108.05 million, a P/E ratio of -16.39 and a beta of 2.73.

Galmed Pharmaceuticals (NASDAQ:GLMD) last issued its quarterly earnings results on Wednesday, May 16th. The biopharmaceutical company reported ($0.17) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.23) by $0.06. Galmed Pharmaceuticals had a negative net margin of 1,073.09% and a negative return on equity of 110.46%. The company had revenue of $0.27 million during the quarter, compared to analysts’ expectations of $0.29 million. equities analysts anticipate that Galmed Pharmaceuticals Ltd will post -0.57 EPS for the current year.

Several institutional investors have recently added to or reduced their stakes in GLMD. A.R.T. Advisors LLC purchased a new stake in shares of Galmed Pharmaceuticals during the 1st quarter worth $107,000. UBS Group AG lifted its position in shares of Galmed Pharmaceuticals by 5,334.8% during the 1st quarter. UBS Group AG now owns 40,000 shares of the biopharmaceutical company’s stock worth $223,000 after purchasing an additional 39,264 shares during the last quarter. Deutsche Bank AG purchased a new stake in shares of Galmed Pharmaceuticals during the 4th quarter worth $246,000. Renaissance Technologies LLC purchased a new stake in shares of Galmed Pharmaceuticals during the 4th quarter worth $345,000. Finally, J. Goldman & Co LP purchased a new stake in shares of Galmed Pharmaceuticals during the 4th quarter worth $569,000. 17.28% of the stock is owned by institutional investors and hedge funds.

About Galmed Pharmaceuticals

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. The company is develops Aramchol, an oral therapy, which is in ARREST study, a Phase IIb clinical study for the treatment of patients with overweight or obesity, and who are pre-diabetic or type-II-diabetic with non-alcoholic steato-hepatitis.

Receive News & Ratings for Galmed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

RPC, Inc.  Shares Bought by JPMorgan Chase & Co.
RPC, Inc. Shares Bought by JPMorgan Chase & Co.
JPMorgan Chase & Co. Has $10.93 Million Stake in Bancorp Inc
JPMorgan Chase & Co. Has $10.93 Million Stake in Bancorp Inc
JPMorgan Chase & Co. Acquires 6,271 Shares of America Movil SAB de CV ADR Series L
JPMorgan Chase & Co. Acquires 6,271 Shares of America Movil SAB de CV ADR Series L
JPMorgan Chase & Co. Increases Holdings in Cracker Barrel Old Country Store, Inc.
JPMorgan Chase & Co. Increases Holdings in Cracker Barrel Old Country Store, Inc.
Joel Isaacson & Co. LLC Has $1.20 Million Stake in Intel Co.
Joel Isaacson & Co. LLC Has $1.20 Million Stake in Intel Co.
13,803 Shares in VANGUARD RUSSELL 3000 ETF  Purchased by Jane Street Group LLC
13,803 Shares in VANGUARD RUSSELL 3000 ETF Purchased by Jane Street Group LLC


Leave a Reply

© 2006-2018 Ticker Report. Google+.